FDA 483 - Patheon Biologics LLC - November 10, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Patheon Biologics LLC, Pharma Services-Thermo Fisher Scientific in Saint Louis, MO, revealed significant deficiencies in their drug substance manufacturing operations. Observations included inadequate and unfollowed standard operating procedures, ineffective corrective and preventive action (CAPA) oversight for recurring issues, and improper labeling of cGMP materials. Additionally, issues with equipment maintenance, stability testing studies, and quality oversight of training were noted, indicating systemic control weaknesses.
ID · 3d352468-eb8e-489c-aaf9-7814b0230ae4